Symbols / TCRT $2.91 -0.68% Alaunos Therapeutics, Inc.
TCRT Chart
About
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.49M |
| Enterprise Value | 5.58M | Income | -4.18M | Sales | 5.00K |
| Book/sh | 1.27 | Cash/sh | 0.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -4.85 | PEG | — |
| P/S | 1298.92 | P/B | 2.29 | P/C | — |
| EV/EBITDA | -1.32 | EV/Sales | 1116.66 | Quick Ratio | 1.71 |
| Current Ratio | 2.44 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.20 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | -25.00% | Earnings | 2025-08-14 16:00 | ROA | -92.31% |
| ROE | -198.10% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -302.33% | Profit Margin | 0.00% | Shs Outstand | 2.23M |
| Shs Float | 1.85M | Short Float | 0.63% | Short Ratio | 0.89 |
| Short Interest | — | 52W High | 6.20 | 52W Low | 1.67 |
| Beta | — | Avg Volume | 20.22K | Volume | 945.00 |
| Target Price | — | Recom | None | Prev Close | $2.93 |
| Price | $2.91 | Change | -0.68% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.00
Latest analyst target
3. DCF / Fair value
$-12.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.00
Low
—
High
—
Mean
—
- Ziopharm: Q4 Earnings Snapshot - kare11.com ue, 31 Mar 2026 22
- TCRT Technical Analysis & Stock Price Forecast - Intellectia AI hu, 02 Apr 2026 07
- TCRT Stock Surge: What To Expect Next? - StocksToTrade hu, 09 Oct 2025 07
- TCRT PE Ratio & Valuation, Is TCRT Overvalued - Intellectia AI Sat, 04 Apr 2026 16
- TCRT Stock Price, News & Analysis - stocktitan.net Fri, 25 Apr 2025 00
- Alaunos Reports Positive Preclinical Data for Obesity Candidate - TipRanks Mon, 02 Mar 2026 08
- TCRT Stock Quote Price and Forecast - CNN Wed, 27 Mar 2024 07
- TCRT 8-K & SEC Filings - Yahoo Finance Singapore Mon, 02 Mar 2026 08
- TCRT - Finviz Sat, 02 Apr 2022 07
- Alaunos Therapeutics, Inc. (TCRT) stock price, news, quote and history - Yahoo Finance UK Wed, 18 Jan 2023 04
- Should I buy Alaunos Therapeutics (TCRT) - Zacks Investment Research Mon, 28 Mar 2022 14
- TCRT Forecast — Price Prediction for 2026. Should I Buy TCRT? - Intellectia AI Wed, 04 Jun 2025 18
- Latest TCRT News - Alaunos Therapeutics Announces Positive Pre... - stocktitan.net ue, 08 Mar 2022 21
- Alaunos Therapeutics, Inc. (TCRT) Stock Price, News, Quote & History - Yahoo! Finance Canada Fri, 25 Mar 2022 14
- What Makes Ziopharm (TCRT) a New Buy Stock - finance.yahoo.com ue, 03 May 2022 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.01
-50.00%
|
0.01
+100.00%
|
0.01
-99.83%
|
2.92
|
| Operating Revenue |
|
0.01
-50.00%
|
0.01
+100.00%
|
0.01
-99.83%
|
2.92
|
| Operating Expense |
|
4.23
-12.28%
|
4.82
-83.08%
|
28.50
-25.32%
|
38.16
|
| Research And Development |
|
1.36
+276.52%
|
0.36
-97.78%
|
16.28
-34.93%
|
25.02
|
| Selling General And Administration |
|
2.87
-35.72%
|
4.46
-63.50%
|
12.22
-7.02%
|
13.14
|
| General And Administrative Expense |
|
2.87
-35.72%
|
4.46
-63.50%
|
12.22
-7.02%
|
13.14
|
| Other Gand A |
|
2.87
-35.72%
|
4.46
-63.50%
|
12.22
-7.02%
|
13.14
|
| Total Expenses |
|
4.23
-12.28%
|
4.82
-83.08%
|
28.50
-25.32%
|
38.16
|
| Operating Income |
|
-4.22
+12.20%
|
-4.81
+83.11%
|
-28.49
+19.14%
|
-35.24
|
| Total Operating Income As Reported |
|
-4.22
+12.20%
|
-4.81
+85.96%
|
-34.27
+2.39%
|
-35.10
|
| EBITDA |
|
-4.22
+12.31%
|
-4.81
+84.44%
|
-30.90
+2.87%
|
-31.82
|
| Normalized EBITDA |
|
-4.19
+12.95%
|
-4.81
+80.86%
|
-25.13
+21.35%
|
-31.95
|
| Reconciled Depreciation |
|
0.01
+250.00%
|
0.00
-99.91%
|
2.31
-16.09%
|
2.76
|
| EBIT |
|
-4.22
+12.20%
|
-4.81
+85.51%
|
-33.22
+3.92%
|
-34.58
|
| Total Unusual Items |
|
-0.03
|
0.00
+100.00%
|
-5.77
-4441.35%
|
0.13
|
| Total Unusual Items Excluding Goodwill |
|
-0.03
|
0.00
+100.00%
|
-5.77
-4441.35%
|
0.13
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-5.77
-4441.35%
|
0.13
|
| Other Special Charges |
|
—
|
—
|
-0.30
-124.06%
|
-0.13
|
| Impairment Of Capital Assets |
|
—
|
0.00
-100.00%
|
4.80
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
0.00
-100.00%
|
1.27
|
0.00
|
| Net Income |
|
-4.18
+10.75%
|
-4.68
+86.68%
|
-35.14
+6.86%
|
-37.73
|
| Pretax Income |
|
-4.18
+10.75%
|
-4.68
+86.68%
|
-35.14
+6.86%
|
-37.73
|
| Net Non Operating Interest Income Expense |
|
—
|
0.00
+100.00%
|
-1.92
+39.09%
|
-3.15
|
| Interest Expense Non Operating |
|
—
|
0.00
-100.00%
|
1.92
-39.09%
|
3.15
|
| Net Interest Income |
|
—
|
0.00
+100.00%
|
-1.92
+39.09%
|
-3.15
|
| Interest Expense |
|
—
|
0.00
-100.00%
|
1.92
-39.09%
|
3.15
|
| Other Income Expense |
|
0.05
-63.16%
|
0.13
+102.81%
|
-4.73
-813.90%
|
0.66
|
| Other Non Operating Income Expenses |
|
0.08
-39.85%
|
0.13
-87.31%
|
1.05
+98.11%
|
0.53
|
| Gain On Sale Of Security |
|
-0.03
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-4.18
+10.75%
|
-4.68
+86.68%
|
-35.14
+6.86%
|
-37.73
|
| Net Income From Continuing Operation Net Minority Interest |
|
-4.18
+10.75%
|
-4.68
+86.68%
|
-35.14
+6.86%
|
-37.73
|
| Net Income From Continuing And Discontinued Operation |
|
-4.18
+10.75%
|
-4.68
+86.68%
|
-35.14
+6.86%
|
-37.73
|
| Net Income Continuous Operations |
|
-4.18
+10.75%
|
-4.68
+86.68%
|
-35.14
+6.86%
|
-37.73
|
| Normalized Income |
|
-4.14
+11.41%
|
-4.68
+84.07%
|
-29.37
+22.44%
|
-37.86
|
| Net Income Common Stockholders |
|
-4.18
+10.75%
|
-4.68
+86.68%
|
-35.14
+6.86%
|
-37.73
|
| Diluted EPS |
|
-2.20
+24.66%
|
-2.92
+86.71%
|
-21.97
+13.84%
|
-25.50
|
| Basic EPS |
|
-2.20
+24.66%
|
-2.92
+86.71%
|
-21.97
+13.84%
|
-25.50
|
| Basic Average Shares |
|
1.95
+21.68%
|
1.60
+0.11%
|
1.60
+10.50%
|
1.45
|
| Diluted Average Shares |
|
1.95
+21.68%
|
1.60
+0.11%
|
1.60
+10.50%
|
1.45
|
| Diluted NI Availto Com Stockholders |
|
-4.18
+10.75%
|
-4.68
+86.68%
|
-35.14
+6.86%
|
-37.73
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
2.97
+7.66%
|
2.75
-66.66%
|
8.26
-87.28%
|
64.94
|
| Current Assets |
|
1.99
-27.84%
|
2.75
-66.65%
|
8.26
-84.64%
|
53.80
|
| Cash Cash Equivalents And Short Term Investments |
|
1.39
+26.95%
|
1.09
-82.00%
|
6.06
-84.48%
|
39.06
|
| Cash And Cash Equivalents |
|
1.39
+26.95%
|
1.09
-82.00%
|
6.06
-84.48%
|
39.06
|
| Receivables |
|
0.00
-40.00%
|
0.01
+400.00%
|
0.00
-75.00%
|
0.00
|
| Accounts Receivable |
|
0.00
-40.00%
|
0.01
+400.00%
|
0.00
-75.00%
|
0.00
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
—
|
—
|
0.00
-100.00%
|
13.94
|
| Other Current Assets |
|
0.60
-63.83%
|
1.66
-24.52%
|
2.20
+175.09%
|
0.80
|
| Total Non Current Assets |
|
0.98
|
0.00
-100.00%
|
0.00
-99.98%
|
11.14
|
| Net PPE |
|
0.09
|
0.00
-100.00%
|
0.00
-99.98%
|
10.60
|
| Gross PPE |
|
0.10
+553.33%
|
0.01
+0.00%
|
0.01
-99.93%
|
20.40
|
| Accumulated Depreciation |
|
-0.01
+53.33%
|
-0.01
-15.38%
|
-0.01
+99.87%
|
-9.81
|
| Properties |
|
—
|
—
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
0.00
-100.00%
|
2.14
|
| Machinery Furniture Equipment |
|
0.00
-100.00%
|
0.01
+0.00%
|
0.01
-99.57%
|
3.47
|
| Construction In Progress |
|
—
|
—
|
—
|
5.23
|
| Other Properties |
|
0.10
|
—
|
—
|
5.23
|
| Leases |
|
—
|
—
|
0.00
-100.00%
|
9.56
|
| Non Current Prepaid Assets |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Other Non Current Assets |
|
0.89
|
—
|
—
|
0.50
|
| Total Liabilities Net Minority Interest |
|
0.81
+17.49%
|
0.69
-64.62%
|
1.96
-92.59%
|
26.38
|
| Current Liabilities |
|
0.81
+17.49%
|
0.69
-64.62%
|
1.96
-91.91%
|
24.17
|
| Payables And Accrued Expenses |
|
0.81
+17.49%
|
0.69
-63.83%
|
1.91
-66.34%
|
5.68
|
| Payables |
|
0.67
+29.26%
|
0.52
-16.23%
|
0.62
-55.65%
|
1.39
|
| Accounts Payable |
|
0.61
+18.80%
|
0.52
-16.23%
|
0.62
-55.65%
|
1.39
|
| Current Accrued Expenses |
|
0.15
-17.05%
|
0.18
-86.43%
|
1.30
-69.80%
|
4.29
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
0.00
-100.00%
|
0.04
-96.29%
|
1.16
|
| Total Tax Payable |
|
0.05
|
0.00
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
17.32
|
| Current Debt |
|
—
|
—
|
—
|
16.77
|
| Other Current Borrowings |
|
—
|
—
|
—
|
16.77
|
| Current Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.56
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
2.22
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
2.19
|
| Long Term Debt |
|
—
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
2.19
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
0.03
|
| Stockholders Equity |
|
2.15
+4.36%
|
2.06
-67.29%
|
6.31
-83.64%
|
38.55
|
| Common Stock Equity |
|
2.15
+4.36%
|
2.06
-67.29%
|
6.31
-83.64%
|
38.55
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
-87.50%
|
0.02
|
| Common Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
-87.50%
|
0.02
|
| Preferred Stock |
|
0.00
|
0.00
|
—
|
—
|
| Share Issued |
|
2.21
+37.76%
|
1.60
+0.00%
|
1.60
-0.09%
|
1.60
|
| Ordinary Shares Number |
|
2.21
+37.76%
|
1.60
+0.00%
|
1.60
-0.09%
|
1.60
|
| Additional Paid In Capital |
|
926.77
+0.46%
|
922.51
+0.05%
|
922.07
+0.32%
|
919.17
|
| Retained Earnings |
|
-924.62
-0.45%
|
-920.45
-0.51%
|
-915.77
-3.99%
|
-880.63
|
| Total Equity Gross Minority Interest |
|
2.15
+4.36%
|
2.06
-67.29%
|
6.31
-83.64%
|
38.55
|
| Total Capitalization |
|
2.15
+4.36%
|
2.06
-67.29%
|
6.31
-83.64%
|
38.55
|
| Working Capital |
|
1.18
-43.04%
|
2.06
-67.28%
|
6.30
-78.72%
|
29.63
|
| Invested Capital |
|
2.15
+4.36%
|
2.06
-67.29%
|
6.31
-88.60%
|
55.32
|
| Total Debt |
|
—
|
—
|
0.00
-100.00%
|
19.51
|
| Capital Lease Obligations |
|
—
|
—
|
0.00
-100.00%
|
2.75
|
| Net Tangible Assets |
|
2.15
+4.36%
|
2.06
-67.29%
|
6.31
-83.64%
|
38.55
|
| Tangible Book Value |
|
2.15
+4.36%
|
2.06
-67.29%
|
6.31
-83.64%
|
38.55
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-2.87
+42.29%
|
-4.97
+83.51%
|
-30.14
-3.11%
|
-29.23
|
| Cash Flow From Continuing Operating Activities |
|
-2.87
+42.29%
|
-4.97
+83.51%
|
-30.14
-3.11%
|
-29.23
|
| Net Income From Continuing Operations |
|
-4.18
+10.75%
|
-4.68
+86.68%
|
-35.14
+6.86%
|
-37.73
|
| Depreciation Amortization Depletion |
|
0.01
+250.00%
|
0.00
-99.91%
|
2.31
-16.09%
|
2.76
|
| Depreciation |
|
0.01
+250.00%
|
0.00
-99.91%
|
2.31
-16.09%
|
2.76
|
| Depreciation And Amortization |
|
0.01
+250.00%
|
0.00
-99.91%
|
2.31
-16.09%
|
2.76
|
| Other Non Cash Items |
|
0.38
|
—
|
1.33
-0.52%
|
1.33
|
| Stock Based Compensation |
|
0.41
-4.83%
|
0.43
-84.46%
|
2.80
-20.63%
|
3.53
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
4.80
|
0.00
|
| Operating Gains Losses |
|
0.03
|
—
|
0.01
+0.00%
|
0.01
|
| Gain Loss On Investment Securities |
|
0.03
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.01
+0.00%
|
0.01
|
| Change In Working Capital |
|
0.47
+164.88%
|
-0.73
+88.34%
|
-6.25
-818.85%
|
0.87
|
| Change In Receivables |
|
0.00
+150.00%
|
-0.00
-233.33%
|
0.00
-99.73%
|
1.11
|
| Change In Prepaid Assets |
|
0.35
-35.06%
|
0.54
+139.72%
|
-1.36
-256.52%
|
0.87
|
| Change In Payables And Accrued Expense |
|
0.12
+109.57%
|
-1.26
+73.46%
|
-4.76
-587.16%
|
-0.69
|
| Change In Accrued Expense |
|
0.02
+102.06%
|
-1.16
+70.82%
|
-3.99
-497.16%
|
-0.67
|
| Change In Payable |
|
0.10
+197.00%
|
-0.10
+87.06%
|
-0.77
-2992.00%
|
-0.03
|
| Change In Account Payable |
|
0.10
+197.00%
|
-0.10
+87.06%
|
-0.77
-2992.00%
|
-0.03
|
| Change In Other Current Assets |
|
—
|
—
|
0.50
+281.68%
|
0.13
|
| Change In Other Current Liabilities |
|
—
|
0.00
+100.00%
|
-0.14
+74.54%
|
-0.54
|
| Investing Cash Flow |
|
-0.10
|
0.00
-100.00%
|
1.35
+797.41%
|
-0.19
|
| Cash Flow From Continuing Investing Activities |
|
-0.10
|
0.00
-100.00%
|
1.35
+797.41%
|
-0.19
|
| Net PPE Purchase And Sale |
|
-0.10
|
0.00
-100.00%
|
1.35
+797.41%
|
-0.19
|
| Purchase Of PPE |
|
-0.10
|
0.00
+100.00%
|
-0.20
+8.80%
|
-0.22
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
1.54
+6608.70%
|
0.02
|
| Capital Expenditure |
|
-0.10
|
—
|
-0.20
+8.80%
|
-0.22
|
| Financing Cash Flow |
|
3.26
|
0.00
+100.00%
|
-18.14
-384.88%
|
6.37
|
| Cash Flow From Continuing Financing Activities |
|
3.26
|
0.00
+100.00%
|
-18.14
-384.88%
|
6.37
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
+100.00%
|
-18.11
-117.27%
|
-8.33
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-18.11
-117.27%
|
-8.33
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-18.11
-117.27%
|
-8.33
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-18.11
-117.27%
|
-8.33
|
| Net Common Stock Issuance |
|
1.91
|
0.00
-100.00%
|
0.09
-99.37%
|
14.68
|
| Common Stock Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.04
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
+100.00%
|
-0.04
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
0.00
-100.00%
|
0.02
|
| Net Other Financing Charges |
|
—
|
—
|
-0.12
|
—
|
| Changes In Cash |
|
0.29
+105.91%
|
-4.97
+89.41%
|
-46.93
-103.55%
|
-23.06
|
| Beginning Cash Position |
|
1.09
-82.00%
|
6.06
-88.56%
|
53.00
-30.32%
|
76.05
|
| End Cash Position |
|
1.39
+26.95%
|
1.09
-82.00%
|
6.06
-88.56%
|
53.00
|
| Free Cash Flow |
|
-2.97
+40.31%
|
-4.97
+83.62%
|
-30.34
-3.03%
|
-29.45
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
-100.00%
|
2.06
-4.97%
|
2.17
|
| Common Stock Issuance |
|
1.91
|
0.00
-100.00%
|
0.09
-99.38%
|
14.72
|
| Issuance Of Capital Stock |
|
3.26
|
0.00
-100.00%
|
0.09
-99.38%
|
14.72
|
| Net Preferred Stock Issuance |
|
1.35
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
1.35
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-31 View
- 8-K2026-03-02 View
- 42026-01-15 View
- 42026-01-15 View
- 42026-01-15 View
- 8-K2026-01-08 View
- 8-K2025-12-23 View
- 42025-11-26 View
- 42025-11-26 View
- 42025-11-26 View
- 10-Q2025-11-14 View
- 42025-08-20 View
- 42025-08-20 View
- 8-K2025-08-20 View
- 10-Q2025-08-14 View
- 8-K2025-07-22 View
- 42025-07-17 View
- 8-K2025-07-17 View
- 8-K2025-07-10 View
- 42025-07-07 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|